TY - JOUR
T1 - Monitoring the quality of life in patients with coronary artery disease
AU - Spertus, John A.
AU - Winder, Jennifer A.
AU - Dewhurst, Timothy A.
AU - Deyo, Richard A.
AU - Fihn, Stephan D.
N1 - Funding Information:
From the Health Services Research and Development program, Seattle Veterans’ Affairs Medical Center and the Department of Internal Medicine, Division,of Cardiology of the University of Washington, Seattle, Washington. This research was supported by HSR&D Project IIR #93-133R and CSHS #7 from the Department of Veterans’ Affairs, Veterans’ Health Administration, Health Services Research and Development Service, Seattle, Washington. Dr. Spertus was a Health Services Research and Development fellow at the Seattle Veterans’ Affairs Medical Center. Manuscript received May 31, 1994; revised manuscript received August 4, 1994, and accepted August 7.
PY - 1994/12/15
Y1 - 1994/12/15
N2 - Monitoring the outcomes of treatment and quantifying patients' functional status have assumed a prominent role in both clinical trials and quality assurance programs. Because patients with coronary artery disease (CAD) may have comorbid illnesses, and because generic health status questionnaires may not focus on symptoms and impairments unique to coronary disease, a generic measure of health status may not be sufficient to detect important changes in patients' CAD. The responsiveness to clinical change of the Seattle Angina Questionnaire (SAQ), a disease-specific measure for CAD, was compared with that of the Short Form-36, a generic measure of health status. Both questionnaires were serially administered, 3 months apart, to 45 patients undergoing coronary angioplasty and to 130 patients with stable CAD. Most scales of both questionnaires improved significantly after coronary angioplasty. The responsiveness statistics of the SAQ exceeded those of the Short Form-36. Among 130 patients with initially stable angina, 33 deteriorated, 79 remained stable, and 18 improved over 3 months of observation. Mean SAQ scores changed significantly and appropriately in each of these groups. In contrast, none of the Short Form-36 scales detected these more subtle changes. Although useful in assessing overall function, a generic health status measure, such as the Short Form-36, may not be responsive enough to detect important clinical changes in patients' CAD. A disease-specific instrument, such as the SAQ, can be an important and relevant outcome measure in clinical trials or quality assurance programs.
AB - Monitoring the outcomes of treatment and quantifying patients' functional status have assumed a prominent role in both clinical trials and quality assurance programs. Because patients with coronary artery disease (CAD) may have comorbid illnesses, and because generic health status questionnaires may not focus on symptoms and impairments unique to coronary disease, a generic measure of health status may not be sufficient to detect important changes in patients' CAD. The responsiveness to clinical change of the Seattle Angina Questionnaire (SAQ), a disease-specific measure for CAD, was compared with that of the Short Form-36, a generic measure of health status. Both questionnaires were serially administered, 3 months apart, to 45 patients undergoing coronary angioplasty and to 130 patients with stable CAD. Most scales of both questionnaires improved significantly after coronary angioplasty. The responsiveness statistics of the SAQ exceeded those of the Short Form-36. Among 130 patients with initially stable angina, 33 deteriorated, 79 remained stable, and 18 improved over 3 months of observation. Mean SAQ scores changed significantly and appropriately in each of these groups. In contrast, none of the Short Form-36 scales detected these more subtle changes. Although useful in assessing overall function, a generic health status measure, such as the Short Form-36, may not be responsive enough to detect important clinical changes in patients' CAD. A disease-specific instrument, such as the SAQ, can be an important and relevant outcome measure in clinical trials or quality assurance programs.
UR - http://www.scopus.com/inward/record.url?scp=0028138854&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028138854&partnerID=8YFLogxK
U2 - 10.1016/0002-9149(94)90555-X
DO - 10.1016/0002-9149(94)90555-X
M3 - Article
C2 - 7977097
AN - SCOPUS:0028138854
SN - 0002-9149
VL - 74
SP - 1240
EP - 1244
JO - American Journal of Cardiology
JF - American Journal of Cardiology
IS - 12
ER -